Company intelligence / Profile preview

FIBICO

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

First Bio-Integrated Corporation (FIBICO) is a Taiwan-based biotechnology company specializing in precision medicine and cell therapy. The company focuses on developing advanced diagnostic tools, such as liquid biopsy for cancer detection, and innovative cell-based treatments. FIBICO aims to integrate biological data with clinical applications to provide personalized healthcare solutions. Their portfolio includes services for genomic profiling and the development of immune cell therapies like CIK and NK cells. The company leverages its proprietary liquid biopsy platform to monitor treatment efficacy and guide clinical decision-making in oncology.

Therapeutic areas: Oncology
Modalities: Cell therapyBiologicDendritic cell therapyNK cell therapy
Industry: Biotech

Partnerships

National Taiwan University Hospital

Beyond the preview

Go deeper on FIBICO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIBICO.

Explore the full profile